Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marco Orlandi is active.

Publication


Featured researches published by Marco Orlandi.


Journal of Clinical Periodontology | 2013

Evidence that periodontal treatment improves biomarkers and CVD outcomes

Francesco D'Aiuto; Marco Orlandi; John C. Gunsolley

AIM The aim of this review was to critically appraise the evidence on the impact of periodontal treatment of cardiovascular diseases (CVDs) biomarkers and outcomes. METHODS A systematic search was performed in Cinhal, Cochrane, Embase and Medline for relevant articles up to July 2012. Duplicate screening and reference hand searching were performed. Data were then summarized and evidence graded in tables. RESULTS The search resulted in: (a) no evidence on the effects of periodontal therapy on subclinical atherosclerosis, serum levels of CD40 ligand, serum amyloid A and monocyte chemoattractant protein-1, (b) limited evidence on the effects of periodontal therapy on arterial blood pressure, leucocyte counts, fibrinogen, tissue necrosis factor-α, sE-selectin, von Willebrand factors, d-dimers, matrix metalloproteinases, oxidative stress and CVD events, and (c) moderate evidence suggesting a negligible effect of periodontal therapy in reducing interleukin-6 and lipids levels, whilst a positive effect in reducing serum C-reactive protein levels and improving endothelial function. CONCLUSIONS Periodontal therapy triggers a short-term inflammatory response followed by (a) a progressive and consistent reduction of systemic inflammation and (b) an improvement in endothelial function. There is however limited evidence that these acute and chronic changes will either increase or reduce CVD burden of individuals suffering from periodontitis in the long term.


PLOS ONE | 2015

Periodontal Therapy and Systemic Inflammation in Type 2 Diabetes Mellitus: A Meta-Analysis

Hilana Paula Carillo Artese; Adriana Moura Foz; Mariana de Sousa Rabelo; Giovane Hisse Gomes; Marco Orlandi; Jean Suvan; Francesco D’Aiuto; Giuseppe Alexandre Romito

Aim The aim of this systematic review was to assess the effect of periodontal therapy (PT) on serum levels of inflammatory markers in people with type 2 diabetes mellitus (T2DM). Methods of Study Selection A literature search was carried out using MEDLINE via Pubmed, EMBASE, LILACS and Cochrane Central Register of Controlled Trials (CENTRAL) databases. Randomized-controlled trials (RCTs) and controlled clinical trials (CCTs) evaluating the effect of PT on systemic inflammatory markers were deemed eligible. Case series (CS), reports and pilot trials were excluded. Study quality was assessed using the Cochrane Collaboration’s risk assessment tool. Meta-analysis was carried out using random effect methods. Results The search strategy identified 3,164 potential studies of which 61 were assessed for eligibility and 9 (6 RCTs and 3 CCTs) were included in this systematic review. Three RCTs were classified by the authors as being at low risk of bias and three were “unclear” and classified as uncertain risk of bias. All CCTs were considered to be at a high risk of bias. The meta-analysis showed a statistically significant mean difference (MD) for TNF- α (-1.33 pg/ml, 95% CI: -2.10; -0.56, p<0.001) and CRP (-1.28 mg/l, 95% CI: -2.07; - 0.48, p<0.001) favoring periodontal intervention versus control. Conclusion The results of this meta-analysis support the hypothesis that PT reduces serum levels of TNF- α and CRP in T2DM individuals. The decrease of inflammatory burden has important implications for metabolic control and can, in part, explain the mechanisms linking periodontitis and increased risk for complications in people with T2DM.


Journal of Clinical Periodontology | 2015

Acute-phase response following full-mouth versus quadrant non-surgical periodontal treatment: A randomized clinical trial.

Filippo Graziani; Silvia Cei; Marco Orlandi; Stefano Gennai; Mario Gabriele; Natalia Filice; Marco Nisi; Francesco D'Aiuto

AIM A moderate acute-phase response occurs 24-h following full-mouth non-surgical treatment (FM-SRP). The aim of this study was to compare acute-phase (24-h) and medium-term (3 months) inflammation after quadrant scaling (Q-SRP) versus FM-SRP. MATERIAL & METHODS Thirty-eight periodontitis-affected subjects were randomly allocated to FM-SRP or Q-SRP after a baseline visit. Periodontal and anthropometric parameters were collected at baseline and 3 months. Serum samples were drawn at baseline, 1, 7, and 90 days after treatment. High-sensitivity assays of inflammation and endothelial assays were performed. RESULTS FM-SRP produced a greater acute-phase response after 24 h [threefold increase in C-reactive protein (CRP), twofold increase in interleukin (IL-6), and a slight increase in tumour necrosis factor]. No differences in systemic biomarkers were noted between groups at any later follow-ups. Both periodontal treatments produced a comparable improvement in clinical periodontal parameters with no between-group differences. Treatment time was positively associated with the relative 24-h increase in CRP (R = 0.5, p < 0.001) and IL-6 (R = 0.5, p = 0.002), while the number of deeper (>6 mm) pockets predicted only the relative increase in IL-6 (R = 0.4, p < 0.05). CONCLUSIONS FM-SRP triggers a moderate acute-phase response of 24 h duration compared to Q-SRP. Further research is needed to assess the eventual impact of such findings on the risk of vascular events is advocated. (ClinicalTrials.gov NCT01857804).


International Journal of Cardiology | 2018

Mitochondrial oxidative stress, endothelial function and metabolic control in patients with type II diabetes and periodontitis: A randomised controlled clinical trial

Stefano Masi; Marco Orlandi; Mohamed Parkar; Devina Bhowruth; Isabel Kingston; Caitriona O'Rourke; Agostino Virdis; Aroon D. Hingorani; Steven J. Hurel; Nikolaos Donos; Francesco D'Aiuto; John E. Deanfield

Background Periodontitis (PD) and type 2 diabetes (T2D) are characterized by increased mitochondrial oxidative stress production (mtROS), which has been associated with a greater risk of cardiovascular diseases (CVD). Intensive PD treatment (IPT) can significantly improve endothelial function and metabolic control, although the mechanisms remain unclear. We explored whether, in patients with PD and T2D, changes of mtROS are associated with improvement of endothelial function and metabolic control after IPT. Methods 51 patients with T2D and PD were enrolled in a single-blind controlled trial and randomised to either intensive (n = 27) or standard (CPT, n = 24) PD treatment. Levels of mtROS in peripheral blood mononuclear cells (PBMC) were measured using a FACS-based assay at baseline and 24 h, 1 week, 2 and 6 months after PD treatment. Inflammatory cytokines, CVD risk factors, metabolic control and endothelial function were assessed at baseline and 6 months after intervention. Results After 6 months from PD treatment, the IPT group had lower mtROS (in both the whole PBMC and lymphocytes), circulating levels of HbA1c, glucose, INF-γ, TNF-α (p < 0.05 for all), and improved endothelial function (p < 0.05) compared to the CPT group. There was an association between higher mtROS and lower endothelial function at baseline (r = −0.39; p = 0.01) and, in the IPT group, changes of mtROS were associated with changes of endothelial function (r = 0.41; p < 0.05). Conclusions Reduced mtROS is associated with improved endothelial function and accompanied by better metabolic control in patients with T2D and PD. mtROS could represent a novel therapeutic target to prevent CVD in T2D.


The Lancet Diabetes & Endocrinology | 2018

Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial

Francesco D'Aiuto; Nikolaos Gkranias; Devina Bhowruth; Tauseef Khan; Marco Orlandi; Jean Suvan; Stefano Masi; Georgios Tsakos; Steve Hurel; Aroon D. Hingorani; Nikos Donos; John Deanfield; Alastair Lomax; A. Horváth; Riccardo Zambon; Shiefung Tay; Nikos Tatarakis; Dave Spratt; Isabel Kingston; Mohamed Parkar; Ulpee Darbar; Kalpesh Patel; Elaine Giedrys-Leeper; Zoë Harrington; Kevin Baynes; Francis J. Hughes; David Gable; Pratik Patel; Ankeet Haria; Michael Lessani

BACKGROUND Chronic inflammation is believed to be a major mechanism underlying the pathophysiology of type 2 diabetes. Periodontitis is a cause of systemic inflammation. We aimed to assess the effects of periodontal treatment on glycaemic control in people with type 2 diabetes. METHODS In this 12 month, single-centre, parallel-group, investigator-masked, randomised trial, we recruited patients with type 2 diabetes, moderate-to-severe periodontitis, and at least 15 teeth from four local hospitals and 15 medical or dental practices in the UK. We randomly assigned patients (1:1) using a computer-generated table to receive intensive periodontal treatment (IPT; whole mouth subgingival scaling, surgical periodontal therapy [if the participants showed good oral hygiene practice; otherwise dental cleaning again], and supportive periodontal therapy every 3 months until completion of the study) or control periodontal treatment (CPT; supra-gingival scaling and polishing at the same timepoints as in the IPT group). Treatment allocation included a process of minimisation in terms of diabetes onset, smoking status, sex, and periodontitis severity. Allocation to treatment was concealed in an opaque envelope and revealed to the clinician on the day of first treatment. With the exception of dental staff who performed the treatment and clinical examinations, all study investigators were masked to group allocation. The primary outcome was between-group difference in HbA1c at 12 months in the intention-to-treat population. This study is registered with the ISRCTN registry, number ISRCTN83229304. FINDINGS Between Oct 1, 2008, and Oct 31, 2012, we randomly assigned 264 patients to IPT (n=133) or CPT (n=131), all of whom were included in the intention-to-treat population. At baseline, mean HbA1c was 8·1% (SD 1·7) in both groups. After 12 months, unadjusted mean HbA1c was 8·3% (SE 0·2) in the CPT group and 7·8% (0·2) in the IPT group; with adjustment for baseline HbA1c, age, sex, ethnicity, smoking status, duration of diabetes, and BMI, HbA1c was 0·6% (95% CI 0·3-0·9; p<0·0001) lower in the IPT group than in the CPT group. At least one adverse event was reported in 30 (23%) of 133 patients in the IPT group and 23 (18%) of 131 patients in the CPT group. Serious adverse events were reported in 11 (8%) patients in the IPT group, including one (1%) death, and 11 (8%) patients in the CPT group, including three (2%) deaths. INTERPRETATION Compared with CPT, IPT reduced HbA1c in patients with type 2 diabetes and moderate-to-severe periodontitis after 12 months. These results suggest that routine oral health assessment and treatment of periodontitis could be important for effective management of type 2 diabetes. FUNDING Diabetes UK and UK National Institute for Health Research.


Atherosclerosis | 2014

Association between periodontal disease and its treatment, flow-mediated dilatation and carotid intima-media thickness: A systematic review and meta-analysis.

Marco Orlandi; Jean Suvan; Aviva Petrie; Nikolaos Donos; S Masi; Aroon D. Hingorani; John Deanfield; Francesco D'Aiuto


Rheumatology | 2018

128 Periodontal disease in systemic lupus erythematosus: is there a link?

Zoe Rutter-Locher; Nicholas R Fuggle; Marco Orlandi; Arvind Kaul; Francesco D'Aiuto; Nidhi Sofat


Rheumatology | 2018

116 Prevalence of periodontitis in patients with rheumatoid arthritis and systemic lupus erythematosus

Marco Orlandi; Jesusa Guinto; Jyoti Bakshi; Alice Cotton; James Wilton; Brett S Bernstein; Francesco D'Aiuto; Coziana Ciurtin


Archive | 2017

Periodontal Disease and Autoimmunity: What We Have Learned from Microbiome Studies in Rheumatology

Zoe Rutter-Locher; Nicholas R. Fuggle; Marco Orlandi; FrancescoD’Aiuto; Nidhi Sofat


In: (Proceedings) Congress of the European-Society-of-Cardiology (ESC). (pp. p. 95). OXFORD UNIV PRESS (2015) | 2015

Impact of periodontitis on endothelial function in patients with type 2 diabetes from different ethnic groups

Devina Bhowruth; T Khan; Nikolaos Gkranias; Marco Orlandi; Jean Suvan; Aroon D. Hingorani; Steven J. Hurel; Nikolaos Donos; John Deanfield; Francesco D'Aiuto

Collaboration


Dive into the Marco Orlandi's collaboration.

Top Co-Authors

Avatar

Francesco D'Aiuto

UCL Eastman Dental Institute

View shared research outputs
Top Co-Authors

Avatar

Jean Suvan

UCL Eastman Dental Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Devina Bhowruth

University College London

View shared research outputs
Top Co-Authors

Avatar

John Deanfield

University College London

View shared research outputs
Top Co-Authors

Avatar

Nikolaos Donos

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Nikolaos Gkranias

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar

Steven J. Hurel

University College London

View shared research outputs
Top Co-Authors

Avatar

Isabel Kingston

University College London

View shared research outputs
Top Co-Authors

Avatar

Mohamed Parkar

University College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge